1. Skaper SD, Facci L, Zusso M, Giusti P. An inflammation-centric view of neurological disease: Beyond the neuron [Internet]. Vol. 12, Frontiers in Cellular Neuroscience. Frontiers Media S.A.; 2018 [cited 2021 Jan 6]. Available from: /pmc/articles/PMC5871676/?report=abstract
2. Tansey MG, Frank-Cannon TC, McCoy MK, Lee JK, Martinez TN, McAlpine FE, et al. Neuroinflammation in Parkinson’s disease: is there sufficient evidence for mechanism-based interventional therapy? Front Biosci [Internet]. 2008 Jan [cited 2014 May 26];13:709–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17981581
3. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability [Internet]. Vol. 20, Cellular and Molecular Neurobiology. Cell Mol Neurobiol; 2000 [cited 2021 Jan 6]. p. 131–47. Available from: https://pubmed.ncbi.nlm.nih.gov/10696506/
4. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001 Dec;24(12):719–25.
5. Borlongan CV, Glover LE, Sanberg PR, Hess DC. Permeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapy. Curr Pharm Des [Internet]. 2012 [cited 2018 Oct 5];18(25):3670. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411920/
6. Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, et al. Blood–brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol [Internet]. 2010 Dec 15 [cited 2018 Oct 5];229(1–2):180–91. Available from: https://www.sciencedirect.com/science/article/pii/S0165572810003759?via%3Dihub
7. Felger JC, Treadway MT. Inflammation Effects on Motivation and Motor Activity: Role of Dopamine. Neuropsychopharmacology [Internet]. 2017;42(1):216–41. Available from: https://doi.org/10.1038/npp.2016.143
8. Zlokovic B V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci [Internet]. 2011 [cited 2017 Apr 11];12(12). Available from: http://www.nature.com/articles/nrn3114
9. Solé M, Esteban-Lopez M, Taltavull B, Fábregas C, Fadó R, Casals N, et al. Blood-brain barrier dysfunction underlying Alzheimer’s disease is induced by an SSAO/VAP-1-dependent cerebrovascular activation with enhanced Aβ deposition. Biochim Biophys Acta - Mol Basis Dis. 2019;
10. Rossi B, Angiari S, Zenaro E, Budui SL, Constantin G. Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J Leukoc Biol [Internet]. 2011 Apr 1 [cited 2017 Apr 11];89(4):539–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21169520
11. Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Willemsen ATM, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol [Internet]. 2005 Feb [cited 2017 Apr 11];57(2):176–9. Available from: http://doi.wiley.com/10.1002/ana.20369
12. Barcia C, Emborg ME, Hirsch EC, Herrero M-T. Blood vessels and parkinsonism. Front Biosci [Internet]. 2004 Jan 1 [cited 2018 Oct 9];9:277–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14766365
13. Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy. Cell Transplant [Internet]. 2007 [cited 2018 Oct 9];16(3):285–99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17503739
14. Fu Q, Song R, Yang Z, Shan Q, Chen W. 6-Hydroxydopamine induces brain vascular endothelial inflammation. IUBMB Life [Internet]. 2017 Nov 1 [cited 2018 Oct 5];69(11):887–95. Available from: http://doi.wiley.com/10.1002/iub.1685
15. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, et al. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci [Internet]. 2005 Sep [cited 2017 Apr 11];22(5):1158–68. Available from: http://doi.wiley.com/10.1111/j.1460-9568.2005.04281.x
16. Sarkar S, Raymick J, Mann D, Bowyer JF, Hanig JP, Schmued LC, et al. Neurovascular changes in acute, sub-acute and chronic mouse models of Parkinson’s disease. Curr Neurovasc Res [Internet]. 2014 Feb [cited 2018 Oct 9];11(1):48–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24274908
17. Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Investig. 2002;82(5):521–33.
18. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science [Internet]. 1992 Sep 4 [cited 2014 Sep 1];257(5075):1407–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1529341
19. Salmi M, Jalkanen S. VAP-1: an adhesin and an enzyme. Trends Immunol [Internet]. 2001 Apr [cited 2014 Sep 1];22(4):211–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11274927
20. Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of Vascular Adhesion Protein 1 Reveals a Novel Multifunctional Adhesion Molecule. J Exp Med [Internet]. 1998 [cited 2018 Oct 5];188(1):17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2525535/
21. Jalkanen S, Salmi M. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol [Internet]. 2008 Jan 1 [cited 2012 Mar 26];28(1):18–26. Available from: http://atvb.ahajournals.org/cgi/content/abstract/28/1/18
22. Tohka S, Laukkanen M, Jalkanen S, Salmi M. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo. FASEB J [Internet]. 2001 Feb;15(2):373–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11156953
23. Yu PH. Deamination of methylamine and angiopathy; toxicity of formaldehyde, oxidative stress and relevance to protein glycoxidation in diabetes. In: The Mother of all Amine Oxidases. Springer Berlin / Heidelberg; 1998.
24. Jaakkola K, Nikula T, Holopainen R, Vähäsilta T, Matikainen MT, Laukkanen ML, et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol [Internet]. 2000 Aug [cited 2014 May 27];157(2):463–71. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1850117&tool=pmcentrez&rendertype=abstract
25. Valente T, Gella A, Solé M, Durany N, Unzeta M. Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer’s disease and diabetes mellitus. J Neurosci Res [Internet]. 2012 Oct [cited 2014 May 27];90(10):1989–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22714978
26. Ferrer I, Lizcano JM, Hernández M, Unzeta M, Herna M. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer’s disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett [Internet]. 2002 Mar 15 [cited 2014 May 27];321(1–2):21–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11872247
27. O’Rourke AM, Wang EY, Salter-Cid L, Huang L, Miller A, Podar E, et al. Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. J Neural Transm [Internet]. 2007 Jan [cited 2012 May 15];114(6):845–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17393060
28. Hernandez-Guillamon M, Solé M, Delgado P, García-Bonilla L, Giralt D, Boada C, et al. VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke. Cerebrovasc Dis [Internet]. 2012 Jan [cited 2012 Mar 29];33(1):55–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22133888
29. Ma Q, Manaenko A, Khatibi NH, Chen W, Zhang JH, Tang J. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J Cereb Blood Flow Metab [Internet]. 2011 Mar [cited 2014 May 27];31(3):881–93. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3063621&tool=pmcentrez&rendertype=abstract
30. Watcharotayangul J, Mao L, Xu H, Vetri F, Baughman VL, Paisansathan C, et al. Post-ischemic vascular adhesion protein-1 inhibition provides neuroprotection in a rat temporary middle cerebral artery occlusion model. J Neurochem [Internet]. 2012 Nov [cited 2014 Feb 7];123 Suppl:116–24. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3481219&tool=pmcentrez&rendertype=abstract
31. Xu H-L, Salter-Cid L, Linnik MD, Wang EY, Paisansathan C, Pelligrino DA. Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia. J Pharmacol Exp Ther [Internet]. 2006 Apr 1 [cited 2014 Sep 1];317(1):19–29. Available from: http://jpet.aspetjournals.org/content/317/1/19.full
32. Elo P, Tadayon S, Liljenbäck H, Teuho J, Käkelä M, Koskensalo K, et al. Vascular adhesion protein-1 is actively involved in the development of inflammatory lesions in rat models of multiple sclerosis. J Neuroinflammation. 2018;15(1):1–17.
33. Zenaro E, Pietronigro E, Bianca V Della, Piacentino G, Marongiu L, Budui S, et al. Neutrophils promote Alzheimer’s disease–like pathology and cognitive decline via LFA-1 integrin. Nat Med [Internet]. 2015 Jul 27 [cited 2017 Apr 11];21(8):880–6. Available from: http://www.nature.com/doifinder/10.1038/nm.3913
34. Salmi M, Jalkanen S. Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation. Antioxid Redox Signal. 2019 Jan;30(3):314–32.
35. Foot JS, Yow TT, Schilter H, Buson A, Deodhar M, Findlay AD, et al. PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo. J Pharmacol Exp Ther [Internet]. 2013 Nov [cited 2014 Jan 21];347(2):365–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23943052
36. Becchi S, Buson A, Foot J, Jarolimek W, Balleine BW. Inhibition of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 reduces lipopolysaccharide-induced neuroinflammation. Br J Pharmacol [Internet]. 2017 Jul 1 [cited 2018 Oct 25];174(14):2302–17. Available from: http://doi.wiley.com/10.1111/bph.13832
37. Castaño A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem [Internet]. 1998 Apr [cited 2014 May 27];70(4):1584–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9580157
38. Herrera AJ, Castaño A, Venero JL, Cano J, Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis [Internet]. 2000 Aug [cited 2018 Oct 25];7(4):429–47. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0969996100902894
39. Bannard C, Leriche M, Bandmann O, Brown CH, Ferracane E, Sánchez-Ferro Á, et al. Reduced habit-driven errors in Parkinson’s Disease. Sci Rep [Internet]. 2019 Dec 1 [cited 2021 Jan 6];9(1). Available from: /pmc/articles/PMC6399280/?report=abstract
40. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The arrive guidelines for reporting animal research. PLoS Biol. 2010;8(6):6–10.
41. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol. 2010;160(7):1577–9.
42. McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE etc.): New requirements for publication in BJP. Br J Pharmacol. 2015;172(13):3189–93.
43. Paxinos G, Watson C. The rat brain in stereotaxic coordinates, 6th Edition | George Paxinos, Charles Watson | ISBN 9780080475158. 2006.
44. Tomás-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis [Internet]. 2004 Jun [cited 2014 May 26];16(1):190–201. Available from: http://www.sciencedirect.com/science/article/pii/S096999610400018X
45. Schmidt-Kastner R, Meller D, Bellander BM, Strömberg I, Olson L, Ingvar M. A one-step immunohistochemical method for detection of blood-brain barrier disturbances for immunoglobulins in lesioned rat brain with special reference to false-positive labelling in immunohistochemistry. J Neurosci Methods [Internet]. 1993 [cited 2020 Sep 20];46(2):121–32. Available from: https://pubmed.ncbi.nlm.nih.gov/8474256/
46. Schallert T, Tillerson JL. Intervention strategies for degeneration of dopamine neurons in Parkinsonism optimizing behavioral assessment of outcome. In: Central Nervous System Diseases. Totowa, NJ: Humana Press Inc.; 2000. p. 131–2.
47. Haghdoost-Yazdi H, Sarookhani M, Faraj A, Fraidouni N, Dargahi T. Pharmacology , biochemistry and behavior evaluation of the association between blood homocysteine concentration and the degree of behavioral symptoms in the 6-hydroxydopamine-induced Parkinsonism in rat. Pharmacol Biochem Behav [Internet]. 2014;124:297–304. Available from: http://dx.doi.org/10.1016/j.pbb.2014.06.020
48. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J Cell Mol Med. 2009;13(9 A):2911–25.
49. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer’s disease. Neurobiol Aging [Internet]. 2007 Jul [cited 2020 Dec 4];28(7):977–86. Available from: https://pubmed.ncbi.nlm.nih.gov/16782234/
50. Gray MT, Woulfe JM. Striatal blood–brain barrier permeability in Parkinson’s disease. J Cereb Blood Flow Metab [Internet]. 2015 May 11 [cited 2018 Oct 30];35(5):747–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25757748
51. Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther [Internet]. 2000 Oct [cited 2018 Oct 25];295(1):125–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10991969
52. Heuer A, Smith GA, Lelos MJ, Lane EL, Dunnett SB. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites. Behav Brain Res [Internet]. 2012;228(1):30–43. Available from: http://dx.doi.org/10.1016/j.bbr.2011.11.027
53. Miyanishi K, Choudhury ME, Watanabe M, Kubo M, Nomoto M, Yano H, et al. Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson’s disease model. Neurochem Int. 2019 Jan;122:38–46.
54. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci [Internet]. 2002 Jan [cited 2014 Dec 27];15(1):120–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11860512
55. Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science. 1977 Aug;197(4303):596–8.
56. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav Brain Res [Internet]. 2005 Jul 1 [cited 2014 Dec 22];162(1):1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15922062
57. Hamby ME, Sofroniew M V. Reactive astrocytes as therapeutic targets for CNS. 2010;7(October):494–506.
58. Cabezas R, Ávila M, Gonzalez J, El-Bachá RS, Báez E, García-Segura LM, et al. Astrocytic modulation of blood brain barrier: Perspectives on Parkinson’s disease. Front Cell Neurosci. 2014;8(AUG):1–11.
59. Alvarez JI, Katayama T, Prat A. Glial influence on the blood brain barrier. Glia. 2013;61(12):1939–58.
60. Flores-Martinez YM, Fernandez-Parrilla MA, Ayala-Davila J, Reyes-Corona D, Blanco-Alvarez VM, Soto-Rojas LO, et al. Acute neuroinflammatory response in the substantia nigra pars compacta of rats after a local injection of lipopolysaccharide. J Immunol Res [Internet]. 2018 May 8 [cited 2018 Oct 31];2018:1–19. Available from: https://www.hindawi.com/journals/jir/2018/1838921/
61. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm Suppl [Internet]. 2000 Jan [cited 2012 Aug 13];(60):277–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11205147
62. Nagatsu T, Sawada M. Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des. 2005;
63. Taylor PR, Martinez-Pomares L, Stacey M, Lin H-H, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol [Internet]. 2005 Apr 27 [cited 2019 Jan 25];23(1):901–44. Available from: http://www.annualreviews.org/doi/10.1146/annurev.immunol.23.021704.115816
64. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol. 2003;106(6):518–26.
65. Picconi B, Gardoni F, Centonze D, Mauceri D, Cenci MA, Bernardi G, et al. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci. 2004;24(23):5283–91.
66. Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson’s disease. Biochim Biophys Acta - Mol Basis Dis [Internet]. 2009 Jul 1 [cited 2018 Oct 24];1792(7):722–9. Available from: https://www.sciencedirect.com/science/article/pii/S0925443908001956?via%3Dihub
67. Redgrave P, Rodriguez M, Smith Y, Rodriguez-Oroz MC, Lehericy S, Bergman H, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson’s disease. Nat Rev Neurosci [Internet]. 2010 Nov;11(11):760–72. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3124757&tool=pmcentrez&rendertype=abstract
68. Dickinson A. Actions and habits: the development of behavioural autonomy. Philos Trans R Soc London B Biol Sci. 1985;308(1135).
69. Balleine BW, Dickinson A. Goal-directed instrumental action: contingency and incentive learning and their cortical substrates. Neuropharmacology [Internet]. 1998 [cited 2017 Feb 28];37(4–5):407–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9704982
70. Balleine BW. The meaning of behavior: discriminating reflex and volition in the brain. Neuron [Internet]. 2019;104(1):47–62. Available from: https://doi.org/10.1016/j.neuron.2019.09.024
71. Lingawi NW, Balleine BW. Amygdala central nucleus interacts with dorsolateral striatum to regulate the acquisition of habits. J Neurosci [Internet]. 2012 Jan 18 [cited 2018 Oct 25];32(3):1073–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22262905
72. Boor PJ, Trent MB, Lyles GA, Tao M, Ansari GA. Methylamine metabolism to formaldehyde by vascular semicarbazide-sensitive amine oxidase. Toxicology. 1992;73(3):251–8.
73. Gubisne-Haberle D, Hill W, Kazachkov M, Richardson JS, Yu PH. Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine. J Pharmacol Exp Ther. 2004 Sep;310(3):1125–32.
74. Spanos M, Gras-Najjar J, Letchworth JM, Sanford AL, Toups JV, Sombers LA. Quantitation of hydrogen peroxide fluctuations and their modulation of dopamine dynamics in the rat dorsal striatum using fast-scan cyclic voltammetry. ACS Chem Neurosci. 2013;4(5):782–9.
75. Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol. 2005 Oct;5(10):760–71.
76. Lalor PF, Sun PJ, Weston CJ, Martin-Santos A, Wakelam MJO, Adams DH. Activation of vascular adhesion protein-1 on liver endothelium results in an NF-κB-dependent increase in lymphocyte adhesion. Hepatology. 2007;45(2):465–74.
77. Choi D-Y, Liu M, Hunter RL, Cass WA, Pandya JD, Sullivan PG, et al. Striatal Neuroinflammation Promotes Parkinsonism in Rats. Gendelman HE, editor. PLoS One [Internet]. 2009 May 8 [cited 2017 Feb 28];4(5):e5482. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19424495
78. Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis [Internet]. 2013;51:35–42. Available from: http://dx.doi.org/10.1016/j.nbd.2012.10.011
79. Chung ES, Chung YC, Bok E, Baik HH, Park ES, Park J-Y, et al. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Res [Internet]. 2010 Dec 2 [cited 2014 May 26];1363:143–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20858471
80. Ferreira Mello BS, Monte AS, McIntyre RS, Soczynska JK, Custódio CS, Cordeiro RC, et al. Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. Vol. 47, Journal of Psychiatric Research. 2013. p. 1521–9.
81. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 1992;41(4):552–6.
82. Yu PH, Zuo DM. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia. 1997;40(11):1243–50.
83. del Mar Hernandez M, Esteban M, Szabo P, Boada M, Unzeta M. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett [Internet]. [cited 2014 May 25];384(1–2):183–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15894424
84. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature [Internet]. 2017;541(7638):481–7. Available from: https://doi.org/10.1038/nature21029
85. Ji K-A, Eu MY, Kang S-H, Gwag BJ, Jou I, Joe E-H. Differential neutrophil infiltration contributes to regional differences in brain inflammation in the substantia nigra pars compacta and cortex. Glia [Internet]. 2008 Aug 1 [cited 2012 Feb 23];56(10):1039–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18381656
86. Li K, Li J, Zheng J, Qin S. Reactive astrocytes in neurodegenerative diseases. Aging Dis. 2019 Jun;10(3):664–75.
87. Lopategui Cabezas I, Herrera Batista A, Pentón Rol G. The role of glial cells in Alzheimer disease: potential therapeutic implications. Neurologia. 2014 Jun;29(5):305–9.
88. Iravani MM, Leung CCM, Sadeghian M, Haddon CO, Rose S, Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci [Internet]. 2005 Jul [cited 2014 May 26];22(2):317–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16045485
89. Lively S, Schlichter LC. Microglia responses to pro-inflammatory stimuli (LPS, IFNγ+TNFα) and reprogramming by resolving cytokines (IL-4, IL-10). Front Cell Neurosci [Internet]. 2018; Available from: www.frontiersin.org
90. Kasten KR, Muenzer JT, Caldwell CC. Neutrophils are significant producers of IL-10 during sepsis. Biochem Biophys Res Commun [Internet]. 2010/01/25. 2010 Feb 26;393(1):28–31. Available from: https://pubmed.ncbi.nlm.nih.gov/20097159
91. Schmidt M, Lügering N, Pauels HG, Schulze-Osthoff K, Domschke W, Kucharzik T. IL-10 induces apoptosis in human monocytes involving the CD95 receptor/ligand pathway. Eur J Immunol. 2000 Jun;30(6):1769–77.
92. Lewkowicz N, Mycko MP, Przygodzka P, Ćwiklińska H, Cichalewska M, Matysiak M, et al. Induction of human IL-10-producing neutrophils by LPS-stimulated Treg cells and IL-10. Mucosal Immunol [Internet]. 2016;9(2):364–78. Available from: https://doi.org/10.1038/mi.2015.66
93. Tremblay P-L, Bedard M-A, Langlois D, Blanchet PJ, Lemay M, Parent M. Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson’s disease. Exp brain Res [Internet]. 2010 Sep [cited 2014 May 26];205(3):375–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20680249
94. Wymbs NF, Bassett DS, Mucha PJ, Porter MA, Grafton ST. Differential recruitment of the sensorimotor putamen and frontoparietal cortex during motor chunking in humans. Neuron [Internet]. 2012 Jun 7 [cited 2014 May 24];74(5):936–46. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3372854&tool=pmcentrez&rendertype=abstract
95. Yin HH, Knowlton BJ, Balleine BW. Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning. Eur J Neurosci [Internet]. 2004 Jan [cited 2017 Feb 28];19(1):181–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14750976
96. Balleine BW, O’Doherty JP. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology [Internet]. 2010 Jan 23 [cited 2018 Oct 25];35(1):48–69. Available from: http://www.nature.com/articles/npp2009131
97. Yin HH, Ostlund SB, Knowlton BJ, Balleine BW. The role of the dorsomedial striatum in instrumental conditioning. Eur J Neurosci [Internet]. 2005 Jul 21 [cited 2017 Feb 28];22(2):513–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16045504